EUCTR2011-001266-17-ES进行中（未招募）不适用
An open-label extension study of the long-term safety,tolerability and efficacy of GSK2402968 in subjects withDuchenne Muscular Dystrophy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Subjects eligible for enrolment in the study must meet all of the following criteria:
- •1. Subjects who have successfully completed either the DMD114117 study or DMD114044 study, OR
- •Subjects who withdrew due to safety/tolerability issues, which have since resolved and where in the opinion of the PI along with consultation of the Medical Monitor, it is considered that the benefit of further treatment with GSK2402968 outweighs the risk to the individual subject. OR
- •Subjects who either complete or withdraw early from studies DMD114117 or DMD114044, who do not wish to continue treatment with GSK2402968 but who are willing to participate in the natural history observation arm.
- •2. Continued use of glucocorticoids with a reasonable expectation that the subject will remain on steroids for the duration of the study. Changes to or cessation of glucocorticosteroids will be at the discretion of the PI in consultation with the subject/parent and the Medical Monitor.
- •3. Willing and able to comply with all protocol requirements and procedures,
- •4. Able to give informed assent and/or consent in writing signed by the subject and/or parent(s)/legal guardian (according to local regulations).
- •5. French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 200
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects meeting any of the following criteria must not be enrolled in the study:
- •1. Subject had a serious adverse experience or who met safety stopping criteria that remains unresolved from DMD114117 or DMD114044, which in the opinion of the investigator could have been attributable to study medication, and which is ongoing at Visit 2. Once resolved, subject may be eligible to enrol following PI consultation with the Medical Monitor.
- •2. Use of anticoagulants, antithrombotics or antiplatelet agents, or previous treatment with investigational drugs except for GSK2402968, within 1 month of the first administration of study medication.
- •3. Current or anticipated participation in any other investigational clinical studies
- •4. History of significant medical disorder which may confound the interpretation of either efficacy or safety data e.g. current or history of renal or liver disease/impairment, history of inflammatory illness.
研究者
相似试验
进行中（未招募）
不适用
An extension study of a drug to treat Chronic Thromboembolic Pulmonary Hypertension (CTEPH)subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH)MedDRA version: 16.0Level: LLTClassification code 10068739Term: Chronic thromboembolic pulmonary hypertensionSystem Organ Class: 100000004855EUCTR2012-001642-17-NLGlaxoSmithKline Research & Developement Ltd160
进行中（未招募）
1 期
A clinical study to provide drisapersen (study medication) to patients with Duchenne disease (muscular disease) and to assess the safety, tolerability and effect by giving the medication long term.Duchenne Muscular Dystrophy (DMD)MedDRA version: 18.1Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-001955-54-DEBioMarin Pharmaceutical Inc.220
进行中（未招募）
不适用
An open-label extension study of the long-term safety,tolerability and efficacy of GSK2402968 in subjects with Duchenne Muscular DystrophyMedDRA version: 14.1Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersDuchenne Muscular DystrophyEUCTR2011-001266-17-Outside-EU/EEAGlaxoSmithKline Research and Development LTD32
进行中（未招募）
1 期
An extension study of a drug to treat Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)Subjects with inoperable Chronic Thromboembolic PulmonaryHypertension (CTEPH)MedDRA version: 17.0Level: LLTClassification code 10068739Term: Chronic thromboembolic pulmonary hypertensionSystem Organ Class: 100000004855EUCTR2012-001642-17-ITGlaxoSmithKline Research & Developement Ltd160
进行中（未招募）
1 期
An extension study of a drug to treat Chronic Thromboembolic Pulmonary Hypertension (CTEPH)subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH)MedDRA version: 14.1 Level: LLT Classification code 10068739 Term: Chronic thromboembolic pulmonary hypertension System Organ Class: 100000004855EUCTR2012-001642-17-GBGlaxoSmithKline Research & Developement Ltd19